- Carl Zeiss Meditec reported Earnings Before Interest, Taxes, and Amortization (EBITA) of €113.6 million for the first half of the year.
- Earnings Per Share (EPS) decreased to €0.70 compared to €0.94 the previous year.
- Total revenue increased by 11% year-over-year, reaching €1.05 billion.
- Revenue from Ophthalmic Devices grew by 15% year-over-year, totaling €808.2 million.
- Microsurgery revenue slightly declined by 1.7%, totaling €242.3 million.
- The EBITA margin stands at 10.8%.
- The company expects continued volatility in the global macroeconomic environment in 2024/25 due to US trade tariffs and currency market fluctuations.
- Carl Zeiss Meditec anticipates moderate revenue growth for the rest of the fiscal year.
- EBITA and the EBITA margin are expected to remain stable or slightly improve in the 2024/25 fiscal year.
- Analyst recommendations include 10 buy ratings, 9 hold ratings, and 2 sell ratings.
A look at Carl Zeiss Meditec Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on Smartkarma Smart Scores, Carl Zeiss Meditec has a promising long-term outlook. With a solid score of 4 for resilience, the company demonstrates a strong ability to weather economic uncertainties and challenges. This indicates that Carl Zeiss Meditec is well-positioned to withstand market fluctuations and continue to deliver consistent performance over time.
Additionally, the company scores decently in value, growth, and momentum, with scores of 3 in each category. This suggests that Carl Zeiss Meditec offers good value for investors, has potential for growth, and shows positive momentum in the market. With its focus on providing innovative medical technology solutions for ophthalmology, Carl Zeiss Meditec is poised for continued success in the global market.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
